Imiquimod for the treatment of actinic keratosis a review of clinical effectiveness and cost-effectiveness
The purpose of this review is to compare the clinical effectiveness and cost-effectiveness of imiquimod (IMQ) compared to other treatment modalities for the treatment of actinic keratosis (AK). This report is the second in the series of three reports on IMQ. The first report was on basal cell and sq...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
Canadian Agency for Drugs and Technologies in Health
2017, September 15, 2017
|
| Edition: | Version 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The purpose of this review is to compare the clinical effectiveness and cost-effectiveness of imiquimod (IMQ) compared to other treatment modalities for the treatment of actinic keratosis (AK). This report is the second in the series of three reports on IMQ. The first report was on basal cell and squamous carcinoma and the third report to follow will be on genital warts |
|---|---|
| Physical Description: | 1 PDF file (33 pages) illustration |